Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | EpCAM (17-1A) |
Clinical data | |
Trade names | Panorex |
ATC code |
|
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
(what is this?) (verify) |
Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).[1][2] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.[3]
Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.